{"id":46066,"date":"2026-03-23T04:09:08","date_gmt":"2026-03-23T04:09:08","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/46066\/"},"modified":"2026-03-23T04:09:08","modified_gmt":"2026-03-23T04:09:08","slug":"hims-hers-faces-profitability-squeeze-after-novo-nordisk-settlement","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/46066\/","title":{"rendered":"Hims &#038; Hers Faces Profitability Squeeze After Novo Nordisk Settlement"},"content":{"rendered":"<p>Hims &amp; Hers resolves legal dispute with Novo Nordisk for weight-loss drug rights, but the shift to branded medications pressures margins and prompts a subdued revenue outlook.<\/p>\n<p>The telehealth company Hims &amp; Hers has resolved its legal dispute with pharmaceutical giant Novo Nordisk, securing official distribution rights for weight-loss medications. While this move ends a contentious chapter involving copycat drugs, it introduces significant financial pressures. Investors are now focusing on a tempered revenue outlook and contracting profit margins.<\/p>\n<p>Legal Scrutiny and Mixed Analyst Sentiment<\/p>\n<p>The company&#8217;s recent past continues to attract legal attention. Last Friday, the law firm Kahn Swick &amp; Foti announced an investigation. The probe will examine whether Hims &amp; Hers management breached its fiduciary duties to shareholders during the conflict over its previous sale of compounded GLP-1 imitation drugs.<\/p>\n<p>Wall Street\u2019s reaction to the company\u2019s evolving situation is divided. While Leerink raised its price target to $25, other analysts point to tangible execution risks. Citigroup noted that Hims &amp; Hers is not listed as an official retail partner on Novo Nordisk\u2019s website. Market experts interpret this as a sign of potential ongoing friction regarding the previous sales strategy.<\/p>\n<p>A Shift in Product Strategy Pressures Margins<\/p>\n<p>The core of the financial challenge stems from a fundamental change in the product lineup. Hims &amp; Hers is discontinuing the sale of its high-margin, compounded GLP-1 formulations. Its platform will now feature the more expensive branded originals, such as Wegovy. This transition is expected to materially impact profitability.<\/p>\n<p>This pressure is already visible in the company\u2019s cash flow statement. Free cash flow turned negative in the fourth quarter, dropping to -$2.6 million. Substantial investments in the company\u2019s own pharmacy infrastructure also contributed to this decline.<\/p>\n<p style=\"margin: 2em 0; color: #374151; font-size: inherit; line-height: 1.6; font-style: italic;\"><a href=\"https:\/\/www.stockstoday.com\/lp\/analysis\/?trk=ST_Asset_Analysis_Middle_RSS-Feed&amp;isin=US4330001060&amp;aktienname=Hims+%26+Hers&amp;adref=Blog_Ad-Hoc-News%3AEx-Article-ID_115654%3AISIN_US4330001060%3AAsset_Hims+%26+Hers%3ASource_Ad-Hoc-News&amp;source=RSS-Ad-Hoc-News&amp;Language=English\" rel=\"noopener nofollow\" style=\"color: #337ab7 !important; font-weight: bold; text-decoration: underline;\" target=\"_blank\">Should investors sell immediately? Or is it worth buying Hims &amp; Hers?<\/a><\/p>\n<p>Subdued Guidance and a Mounting Financial Challenge<\/p>\n<p>For the closing quarter, the firm posted solid revenue growth, reaching nearly $618 million. However, its outlook for the current first quarter of 2026 is more cautious, projecting revenue between $600 million and $625 million\u2014a range that fell short of analyst expectations. Management attributes this conservative guidance directly to the forced product shift.<\/p>\n<p>The company now faces a clear arithmetic hurdle. The lower-margin profile of the official medications will require a significant increase in sales volume among its existing base of 2.5 million subscribers to meet its 2026 profitability targets. This effort unfolds within a defined financial framework, with approximately $1 billion in debt\u2014primarily from a convertible note\u2014on the balance sheet.<\/p>\n<p>The stock recently retreated nearly nine percent as some investors locked in gains, reflecting the market&#8217;s reassessment of the company&#8217;s near-term path forward.<\/p>\n<p align=\"right\" style=\"font-size:10px;margin:0;\">Ad<\/p>\n<p style=\"margin-bottom: 1em;\">Hims &amp; Hers Stock: New Analysis &#8211; 23 March<\/p>\n<p style=\"margin-bottom: 1em;\">Fresh Hims &amp; Hers information released. What&#8217;s the impact for investors? Our latest independent report examines recent figures and market trends.<\/p>\n<p style=\"margin-bottom: 1em;\"><a href=\"https:\/\/www.stockstoday.com\/lp\/analysis\/?trk=ST_Asset_Analysis_Bottom_RSS-Feed&amp;isin=US4330001060&amp;aktienname=Hims+%26+Hers&amp;adref=Blog_Ad-Hoc-News%3AEx-Article-ID_115654%3AISIN_US4330001060%3AAsset_Hims+%26+Hers%3ASource_Ad-Hoc-News&amp;source=RSS-Ad-Hoc-News&amp;Language=English\" rel=\"noopener nofollow\" style=\"color: #337ab7 !important; font-weight: bold; text-decoration: underline;\" target=\"_blank\">Read our updated Hims &amp; Hers analysis&#8230;<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Hims &amp; Hers resolves legal dispute with Novo Nordisk for weight-loss drug rights, but the shift to branded&hellip;\n","protected":false},"author":2,"featured_media":46067,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[9714,9853,5696,621,5691,3845,272,26173,26175,26174],"class_list":["post-46066","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-after","tag-faces","tag-hers","tag-hims","tag-nordisk","tag-novo","tag-novo-nordisk","tag-profitability","tag-settlement","tag-squeeze"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116276531190105504","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/46066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=46066"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/46066\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/46067"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=46066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=46066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=46066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}